spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  T-cell therapy 

 HSMN NewsFeed - 28 Feb 2023
Verismo Therapeutics Announces $7 Million Pre-Series A with BRV Capital Management as Lead Investor
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 31 Oct 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Aug 2022
Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110TM, a KIR-CAR T-cell Immunotherapy Candidate
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Biopharmaceutical Personnel
 HSMN NewsFeed - 2 Nov 2020
CARsgen Therapeutics Closes a USD 186 Million Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Oct 2020
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Apr 2020
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Apr 2020
Digital Therapeutics Leader Biofourmis Expands into Oncology Market with Strategic Acquisition of Gaido Health
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Biopharmaceuticals Oncology Licensing Acquisitions
 HSMN NewsFeed - 3 Apr 2017
Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jan 2017
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jan 2014
Lion Biotechnologies Appoints James Bender, Ph.D., as Vice President, Product Development and Manufacturing
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Nov 2013
Lion Biotechnologies Completes $23.3 Million Private Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Feb 2013
Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna(TM) (imilecleucel-T) for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 21 May 2012
Opexa Therapeutics Announces Tcelna(TM) as New Brand Name for MS Therapy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Sep 2011
Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2009
Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin(R) Development in Multiple Sclerosis
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 21 Mar 2008
Opexa Therapeutics Announces Retirement of CEO David McWilliams
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Sep 2007
Opexa Therapeutics Gives Update on Phase IIb Trial of Tovaxin(R) for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 May 2007
Opexa Therapeutics Completes Patient Enrollment in Phase IIb Trial of Tovaxin(TM) for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
T-cell therapy
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.